Skip to main content
. 2023 Apr 10;14(15):1339–1347. doi: 10.1111/1759-7714.14875

TABLE 2.

Treatment and progression of the study patients.

Variables Total Type B2 Type B2 + B3 Type B3
Residual disease
R0 217 (91.9%) 128 (96.2%) 36 (92.3%) 53 (82.8%)
R1/R2 7 (3.0%) 1 (0.8%) 1 (2.6%) 5 (7.8%)
Progression
Yes 23 (9.7%) 12 (9.0%) 4 (10.3%) 7 (10.9%)
No 203 (86.0%) 113 (85.0%) 34 (87.2%) 56 (87.5%)
Postoperative therapy
Radiotherapy 107 (45.3%) 54 (40.6%) 17 (43.6%) 36 (56.3%)
Chemotherapy 14 (5.9%) 3 (2.3%) 6 (15.4%) 5 (7.8%)
Concurrent chemoradiation 2 (0.8%) 1 (0.8%) 1 (2.6%) 0 (0.0%)
Chemotherapy + radiotherapy 7 (3.0%) 0 (0.0%) 2 (5.1%) 5 (7.8%)
Radiotherapy + chemotherapy 9 (3.8%) 3 (2.3%) 1 (2.6%) 5 (7.8%)
None 85 (36.0%) 62 (46.6%) 11 (28.2%) 12 (18.8%)